Factor XII - a drug target for safe interference with thrombosis and inflammation

Ellinor Kenne; Thomas Renné

doi:10.1016/j.drudis.2014.06.024

Factor XII - a drug target for safe interference with thrombosis and inflammation

Standard

Factor XII - a drug target for safe interference with thrombosis and inflammation. / Kenne, Ellinor; Renné, Thomas.

in: DRUG DISCOV TODAY, Jahrgang 19, Nr. 9, 01.09.2014, S. 1459-64.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kenne, E & Renné, T 2014, 'Factor XII - a drug target for safe interference with thrombosis and inflammation', DRUG DISCOV TODAY, Jg. 19, Nr. 9, S. 1459-64. https://doi.org/10.1016/j.drudis.2014.06.024

APA

Kenne, E., & Renné, T. (2014). Factor XII - a drug target for safe interference with thrombosis and inflammation. DRUG DISCOV TODAY, 19(9), 1459-64. https://doi.org/10.1016/j.drudis.2014.06.024

Vancouver

Kenne E, Renné T. Factor XII - a drug target for safe interference with thrombosis and inflammation. DRUG DISCOV TODAY. 2014 Sep 1;19(9):1459-64. https://doi.org/10.1016/j.drudis.2014.06.024

Bibtex

@article{cbf8e9ae795d4ff2a2fe3d732fb8b63b,

title = "Factor XII - a drug target for safe interference with thrombosis and inflammation",

abstract = "Data from experimental animal models revealed an essential role for factor XII (FXII) in thrombotic occlusive diseases. In contrast to other blood coagulation factors, deficiency in the protease is not associated with abnormal bleeding from injury sites (hemostasis) in patients or in animals. Cumulatively, these findings suggest that FXII could be targeted as a new method of anticoagulation that is devoid of bleeding risks. An FXIIa-neutralizing antibody, 3F7, has been developed that inhibited thrombosis in an extracorporeal membrane oxygenation (ECMO) system as efficiently as heparin. However, in sharp contrast to heparin, 3F7 treatment was not associated with an increase in therapy-associated hemorrhage. In this review, we summarize current knowledge of FXII physiology and pharmacology.",

keywords = "Animals, Antibodies, Anticoagulants, Disease Models, Animal, Extracorporeal Membrane Oxygenation, Factor XII, Factor XIIa, Hemorrhage, Heparin, Humans, Inflammation, Thrombosis",

author = "Ellinor Kenne and Thomas Renn{\'e}",

year = "2014",

month = sep,

day = "1",

doi = "10.1016/j.drudis.2014.06.024",

language = "English",

volume = "19",

pages = "1459--64",

journal = "DRUG DISCOV TODAY",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "9",

}

RIS

TY - JOUR

T1 - Factor XII - a drug target for safe interference with thrombosis and inflammation

AU - Kenne, Ellinor

AU - Renné, Thomas

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Data from experimental animal models revealed an essential role for factor XII (FXII) in thrombotic occlusive diseases. In contrast to other blood coagulation factors, deficiency in the protease is not associated with abnormal bleeding from injury sites (hemostasis) in patients or in animals. Cumulatively, these findings suggest that FXII could be targeted as a new method of anticoagulation that is devoid of bleeding risks. An FXIIa-neutralizing antibody, 3F7, has been developed that inhibited thrombosis in an extracorporeal membrane oxygenation (ECMO) system as efficiently as heparin. However, in sharp contrast to heparin, 3F7 treatment was not associated with an increase in therapy-associated hemorrhage. In this review, we summarize current knowledge of FXII physiology and pharmacology.

AB - Data from experimental animal models revealed an essential role for factor XII (FXII) in thrombotic occlusive diseases. In contrast to other blood coagulation factors, deficiency in the protease is not associated with abnormal bleeding from injury sites (hemostasis) in patients or in animals. Cumulatively, these findings suggest that FXII could be targeted as a new method of anticoagulation that is devoid of bleeding risks. An FXIIa-neutralizing antibody, 3F7, has been developed that inhibited thrombosis in an extracorporeal membrane oxygenation (ECMO) system as efficiently as heparin. However, in sharp contrast to heparin, 3F7 treatment was not associated with an increase in therapy-associated hemorrhage. In this review, we summarize current knowledge of FXII physiology and pharmacology.

KW - Animals

KW - Antibodies

KW - Anticoagulants

KW - Disease Models, Animal

KW - Extracorporeal Membrane Oxygenation

KW - Factor XII

KW - Factor XIIa

KW - Hemorrhage

KW - Heparin

KW - Humans

KW - Inflammation

KW - Thrombosis

U2 - 10.1016/j.drudis.2014.06.024

DO - 10.1016/j.drudis.2014.06.024

M3 - SCORING: Journal article

C2 - 24993156

VL - 19

SP - 1459

EP - 1464

JO - DRUG DISCOV TODAY

JF - DRUG DISCOV TODAY

SN - 1359-6446

IS - 9

ER -